Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer

STATUS

Recruiting
participants needed

60
sponsor

Memorial Sloan Kettering Cancer Center

Send

Updated on 19 February 2024

See if I qualify

cancer

ovarian cancer

carcinoma

ovarian carcinoma

Summary

The researchers are doing this study to find out whether the researchers can combine information provided by PET/MRI scans with information from tests on blood and tissue samples to develop a very detailed description (profile) of high-grade serous ovarian carcinoma (HGSOC), which could improve our ability to treat this disease.

The study researchers will use computers to analyze the combined results of the imaging tests and the genetic and immune system tests on the tumor samples. The study researchers think that this information will help them more accurately predict the way tumors respond to treatment, which may improve their ability to individualize treatments for this disease.

Details

Condition	Ovarian disorder, Ovarian Cancer, Ovarian Cancer, High Grade Ovarian Serous
Age	18years - 100years
Treatment	PET/MRI, Contrast enhanced CT
Clinical Study Identifier	NCT04454450
Sponsor	Memorial Sloan Kettering Cancer Center
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	years of age or older
	Histologically confirmed or clinically suspected FIGO stage IIIC-IV HGSOC
	Signed consent to MSK Institutional biospecimen protocols IRB 06-107 and 12-245, and planned to undergo multi-region tissue collection [under the above IRB protocols] and subsequent tissue analysis under IRB 15-200
	Staging standard-of-care contrast-enhanced CT of abdomen and pelvis (+/-chest) available in picture archiving and communication system (PACS) that was obtained at our institution as a part of standard-of-care work-up or submitted for from the outside
	Plasma glucose 200 mg/dL
	Negative pregnancy test, if a patient is of child-bearing potential
Exclusion Criteria
	Known allergy to gadolinium-based contrast medium requiring premedication or known adverse reactions to gadolinium-based contrast medium
	Known history of impaired renal function, with documented eGFR <30 within 30 days prior to PET/MRI
	Patients who cannot give valid informed consent because of general medical or physical condition, or physiologic status unrelated to presence of ovarian cancer
	Patients who are unwilling or unable to undergo PET/MRI including patients with absolute or relative contraindications to MRI including breast tissue expanders, cardiac pacemakers and defibrillators, non MRI-compatible aneurysm clips, neurostimulators, programmable CSF shunts, vascular stents, claustrophobia, or inability to lie flat for the duration of the examination
	Patients with metallic hardware, implant, or device in the abdomen or pelvis that might distort the local magnetic field and compromise image quality
	Radiotherapy to the abdomen or pelvis within 12 months of the screening visit
	Subjects with a current diagnosis of ovarian cancer other than HGSOC
	Patients with known synchronous primary endometrial cancer or past history of endometrial cancer
	Patients who have received prior chemotherapy for any abdominal or pelvic tumor. Patients may have received prior adjuvant chemotherapy for breast cancer
	With the exception of non-melanoma skin cancer and other specific malignancies as noted above, subjects with other invasive malignancies who had (or have) any evidence of the other cancer present within the last 3 years are excluded
	Unresolved bowel obstruction
	History or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study or interfere with patient's participation for the full duration of the study
	Absence of any target lesions ( 1-2 cm) in the pelvis (right adnexa, left adnexa, infra-colic omentum, pelvic peritoneum) visible on staging standard-of-care CE-CT and accessible for tissue sampling at laparoscopy and/or primary/ interval debulking surgery

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

I am at least 18 years old.

By sending a message, I agree to share my information with the study team for the selected site and consent to receive emails and text messages for trial updates, notifications, and related communication. TrialX values your privacy; your information will be handled in accordance with our Privacy Policy

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Using Advanced Imaging Studies to Develop a Profile of High-grade Serous Ovarian Cancer